-
Published 9/22/2026
Lazzaro A, Nannini K, Yildirim C, Huhmann L, Culnan JM, Corrigan JK, Elbers D, Do NV, Brophy M, Munshi N, Fillmore NR, Edwards CV. Evolution of real-world frontline treatment patterns in multiple myeloma. Blood Adv. 2026 Sep 22; 10(18):6278-6288. PMID: 42480210.
-
Published 9/17/2026
Yellanki M, La J, Elbers DC, Do NV, Paller CJ, Fillmore NR, Schoen MW. Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer. Prostate. 2026 Sep 17. PMID: 42752817.
-
Published 9/9/2026
Huhmann LB, Hwang JC, Lu C, Perez D, Burke O, Thang CJ, Khattab S, Nguyen N, Beagles E, Cheng D, Goryachev SD, Weinstock MA, Asgari MM, Feldman TC, Do NV, Gaziano JM, Hurlbert MS, Semenov YR, Fillmore NR, Hartman RI. Prior keratinocyte carcinoma as a risk factor for mucosal melanoma: A multi-institutional retrospective case-control study of Veterans and civilians in the Veterans Health Administration and Mass General Brigham. J Am Acad Dermatol. 2026 Sep 09. PMID: 42716118.
-
Published 9/8/2026
Lee G, Bihn JR, Culnan JM, La J, Do NV, Myrie K, Paller CJ, Fillmore NR, Cooperberg MR. Active Surveillance Use for Favorable-Risk Prostate Cancer in a Veterans Affairs Population. JAMA. 2026 Sep 08; 336(10):884-886. PMID: 42593769.
-
Published 9/2/2026
Amadori L, Calcagno C, Kaur R, Horstmann H, He T, Gildea M, Sakurai K, Chong PS, Shamailova R, Naidu S, Hill CA, Sajja S, Bresciani J, La Forest M, Ghotbi AA, Soler R, Faries C, Fisher EA, Fayad ZA, Fillmore NR, Ramos-Cejudo J, Readhead B, Dudley JT, Bjorkegren JLM, Giannarelli C. Gene regulatory network analysis identifies auranofin as an anti-atherosclerotic drug. Nat Commun. 2026 Sep 02; 17(1). PMID: 42823455.